Sunday, February 10, 2013

Watch talks from Gabe Newell to Ray Muzyka in the collected DICE 2013 presentations, right here

Watch talks from Gabe Newell to Ray Muzyka in the collected DICE 2013 keynotes, right here

This year's DICE was especially heavy on great speakers, and we're happy to say that a partnership between The Academy of Interactive Arts & Sciences and entertainment trade publication Variety means that most of the great speeches were captured for all to see on YouTube. That means everything from Valve head Gabe Newell's speech on his company's next steps in the hardware realm to Microsoft's discussion of the latest, greatest Halo game -- and even a surprise appearance from the recently retired BioWare doctor, Ray Muzyka -- was recorded. We've dropped the available talks just below the break; sadly, the first day's J.J. Abrams / Gabe Newell back-and-forth on storytelling was an in-person exclusive. We'll have a variety of interviews from DICE with many of the speakers seen beyond the break in the coming days -- keep an eye out (or a bookmark here, of course)!

Filed under: , ,

Comments

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/5-vtXi6Pbic/

bracket vangogh yield crossbow airhead atherosclerosis steven tyler

IRL: Mailbox, Behringer iNuke Boom Junior and the Fujifilm X-E1

Welcome to IRL, an ongoing feature where we talk about the gadgets, apps and toys we're using in real life and take a second look at products that already got the formal review treatment.

You may have heard that a little app called Mailbox launched a few days ago. You may have also heard it's the greatest thing since sliced bread. As it turns out, Darren hates it. Fortunately, it's not all doom and gloom this week: Jason's impressed with the miniaturized iNuke Boom Junior speaker, and Philip is just happy to answer questions about his new camera.

Filed under:

Comments

Source: http://feeds.engadget.com/~r/weblogsinc/engadget/~3/v0Z4jrspyfQ/

Nolan Daniels angus t. jones monday night football monday night football SEC Championship Game 2012 kansas city chiefs Javon Belcher

Saturday, February 9, 2013

Scientists prevent development of deafness in animals engineered to have Usher syndrome

Feb. 4, 2013 ? Hearing impairment is the most common sensory disorder, with congenital hearing impairment present in approximately 1 in 1,000 newborns, and yet there is no physiological cure for children who are born deaf. Most cases of congenital deafness are due to a mutation in a gene that is required for normal development of the sensory hair cells in the inner ear that are responsible for detecting sound. To cure deafness caused by such mutations, the expression of the gene must be corrected, a feat that has been elusive until recently.

Rosalind Franklin University of Medicine and Science (RFUMS) Assistant Professor Michelle Hastings and her team, along with investigators at Louisiana State University Health Sciences Center in New Orleans, Louisiana and Isis Pharmaceuticals in Carlsbad, CA, have now found a way to target gene expression in the ear and rescue hearing and balance in mice that have a mutation that causes deafness in humans. The results of the study are reported in the paper, Rescue of hearing and vestibular function in a mouse model of human deafness, which was published February 4, 2013 in the journal Nature Medicine.

Dr. Hastings collaborated with research leaders across the country, including RFUMS colleagues Francine Jodelka and Anthony Hinrich, who were co-first authors on the study, as well as Dr. Dominik Duelli and Kate McCaffrey; co-first author Dr. Jennifer Lentz at Louisiana State University Health Sciences Center New Orleans, and Dr. Lentz's research team, including Drs. Hamilton Farris and Nicolas Bazan and Matthew Spalitta; and Dr. Frank Rigo at Isis Pharmaceuticals. The collaboration led to the development of a novel therapeutic approach to treat deafness and balance impairment by injecting mice with a single dose of a small, synthetic RNA-like molecule, called an antisense oligonucleotide (ASO). The ASO was designed to specifically recognize and fix a mutation in a gene called USH1C, that causes Usher syndrome in humans. The ASO blocks the effect of the mutation, allowing the gene product to function properly, thereby preventing deafness.

Usher syndrome is the leading genetic cause of combined deafness and blindness in humans. Treatment of these Usher mice with the ASO early in life rescues hearing and cures all balance problems. "The effectiveness of the ASO is striking," states Hastings. "A single dose of the drug to newborn mice corrects balance problems and allows these otherwise deaf mice to hear at levels similar to non-Usher mice for a large portion of their life," she says.

Validating ASO efficacy in the Usher mice is an important step in the process of developing the strategy for human therapy. Dr. Lentz, who has been studying Usher syndrome for almost 10 years and engineered the mice to model the human disease, states, "Successfully treating a human genetic disease in this animal model brings the possibility of treating patients much closer."

The results of the study demonstrate the therapeutic potential of this type of ASO in the treatment of deafness and provide evidence that congenital deafness can be effectively overcome by treatment early in development to correct gene expression.

"The discovery of an ASO-type drug that can effectively rescue hearing opens the door to developing similar approaches to target and cure other causes of hearing loss," says Dr. Hastings who has been awarded a grant from the National Institute of Health to further develop the ASOs for the treatment of deafness with Drs. Lentz, Rigo and Duelli.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Rosalind Franklin University of Medicine and Science, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/most_popular/~3/5nMbDKSLo7M/130208152806.htm

school shooting in ohio shooting at chardon high school sasha baron cohen stacy keibler stacy keibler all star game oscar red carpet

EU leaders to agree push for U.S. trade deal

BRUSSELS (Reuters) - Europe's leaders will agree on Friday to push for a free-trade pact with the United States, according to a draft joint statement, putting the onus on the White House to respond to a proposal that would encompass half the world's economic output.

Major exporters Germany and Britain appear to have won support from the rest of the European Union at a summit in Brussels to reach a deal with Washington that many leaders hope will help Europe pull out of its banking and debt crises.

According to the draft of the final summit statement obtained by Reuters, the European Union will give "its support for a comprehensive trade agreement" with the United States.

"All efforts should be devoted to pursuing agreements with key partners," EU leaders will say, putting the United States at the top of a long list including Japan and Canada.

The EU leaders' statement raises expectations that U.S. President Barack Obama may endorse the initiative next Tuesday in his annual State of the Union speech, which presidents traditionally use to lay out their priorities for the year.

Obama and EU leaders tasked their trade chiefs in 2011 to look at whether it was feasible to agree a deal to further integrate the two blocs that already have low tariffs.

A U.S.-EU draft proposal drawn up by EU Trade Commissioner Karel De Gucht and U.S. Trade Representative Ron Kirk is essentially ready. De Gucht, who went to Washington this week, has given strong signals that there is enough common ground to go ahead with negotiations.

Talks could start in months, and while such negotiations are notoriously slow, both sides appear to want to agree on an accord quickly, possibly by the end of 2014.

But U.S. officials, wary of getting bogged down in endless talks, have said they need a strong political commitment from the 27-nation European Union that Brussels is serious about opening up its markets before they can go ahead with talks.

The EU's formal commitment will come later on Friday when the summit, largely focused on efforts to agree the EU's seven-year budget, wraps up with a final statement.

German Chancellor Angela Merkel, with support from free-trade advocate Britain, has been eager for a deal for months.

"I wish for nothing more than a free-trade agreement with the United States," Merkel said on January 29 in Berlin.

Diplomats say the time is right for a deal that was first talked about three decades ago but was considered too difficult because of worries from protectionists on both sides of the Atlantic, especially the farming sector.

In a speech on Saturday in Munich, U.S. Vice President Joe Biden said the economic benefits of a comprehensive trade agreement would be "almost boundless" if the two sides could muster the political will to resolve longstanding differences in regulations that have blocked farm and other exports.

Biden said: "This is within our reach."

(Additional reporting by Doug Palmer in Washington; Editing by Oliver Holmes)

Source: http://news.yahoo.com/eu-leaders-agree-push-u-trade-deal-101838521--finance.html

mega millions jackpot black panther party frank martin pink slime eagle cam trayvon martin case affordable care act

Friday, February 8, 2013

Unique peptide has therapeutic potential against cancers, neurological disorders, and infectious diseases

Feb. 7, 2013 ? UT Southwestern Medical Center scientists have synthesized a peptide that shows potential for pharmaceutical development into agents for treating infections, neurodegenerative disorders, and cancer through an ability to induce a cell-recycling process called autophagy.

Autophagy is a fundamental recycling process in which intracellular enzymes digest unneeded and broken parts of the cell into their individual building blocks, which are then reassembled into new parts. The role of autophagy is crucial both in keeping cells healthy and in enabling them to fight different diseases. Physician scientists in UT Southwestern's Center for Autophagy Research are deciphering how to manipulate the autophagy process in an effort to disrupt the progression of disease and promote health.

In their latest findings reported online in the journal Nature, Center researchers were able to synthesize a peptide called Tat-beclin 1, which induces the autophagy process. Mice treated with Tat-beclin-1 were resistant to several infectious diseases, including West Nile virus and another mosquito-borne virus called chikungunya that is common to Asia, Africa, and India. In additional experiments, the team demonstrated that human cells treated with the peptide were resistant to HIV infection in a laboratory setting.

"Because autophagy plays such a crucial role in regulating disease, autophagy-inducing agents such as the Tat-beclin 1 peptide may have potential for pharmaceutical development and the subsequent prevention and treatment of a broad range of human diseases," said Dr. Beth Levine, Director of the Center for Autophagy Research and senior author of the study. Dr. Levine, Professor of Internal Medicine and Microbiology, is a Howard Hughes Medical Institute investigator at UT Southwestern.

Disruption of the autophagy process is implicated in a wide variety of conditions including aging, and diseases, including cancers, neurodegenerative diseases such as Parkinson's and Alzheimer's, and infectious diseases such as those caused by West Nile and HIV viruses.

UT Southwestern has applied for a patent on Tat-beclin-1. Peptides are strings of amino acids found in proteins. The Tat-beclin 1 peptide was derived from sequences in beclin 1, one of the first known proteins in mammals found to be essential for autophagy, a finding that was made by Dr. Levine's laboratory. Her research has since demonstrated that defects in beclin 1 contribute to many types of disease. Conversely, beclin 1 activity and the autophagy pathway appear to be important for protection against breast, lung, and ovarian cancers, as well as for fighting off viral and bacterial infections, and for protecting individuals from neurodegenerative diseases and aging.

The study was supported by grants from the National Institutes of Health, the National Science Foundation, the HHMI, the Netherlands Organization for Scientific Research-Earth and Life Sciences Open Program, Cancer Research United Kingdom, and a Robert A. Welch Foundation Award.

Other UT Southwestern scientists involved include Dr. Sanae Shoji-Kawata, first author and former postdoctoral researcher now in Japan; Dr. Rhea Sumpter Jr., an instructor of internal medicine and member of the autophagy center; Dr. Matthew Leveno, assistant professor of internal medicine and autophagy center member; Dr. Carlos Huerta, former postdoctoral researcher of biochemistry now at Reata Pharmaceuticals; Dr. Nick Grishin, professor of biochemistry and HHMI investigator; Dr. Lisa Kinch, bioinformatics scientist; Zhongju Zou, research specialist; and Quhua Sun, computational biologist.

Researchers from the University of California, San Diego; Rady Children's Hospital-San Diego; Baylor College of Medicine in Houston; Washington University School of Medicine in St. Louis; Utrecht University, Utrecht, The Netherlands; Cancer Research UK, London; Massachusetts General Hospital, Harvard Medical School; the Broad Institute of Harvard and Massachusetts Institute of Technology; Columbia University College of Physicians and Surgeons; the HHMI; and University of California, Berkeley, also participated in the study.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by UT Southwestern Medical Center, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. Sanae Shoji-Kawata, Rhea Sumpter, Matthew Leveno, Grant R. Campbell, Zhongju Zou, Lisa Kinch, Angela D. Wilkins, Qihua Sun, Kathrin Pallauf, Donna MacDuff, Carlos Huerta, Herbert W. Virgin, J. Bernd Helms, Ruud Eerland, Sharon A. Tooze, Ramnik Xavier, Deborah J. Lenschow, Ai Yamamoto, David King, Olivier Lichtarge, Nick V. Grishin, Stephen A. Spector, Dora V. Kaloyanova, Beth Levine. Identification of a candidate therapeutic autophagy-inducing peptide. Nature, 2013; DOI: 10.1038/nature11866

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/gh-rJUYkpTs/130207093006.htm

Ernie Els Teen Choice Awards 2012 Aurora victims usher James Holmes Minka Kelly sex tape Colorado shooting

Video: Remembering Joe Musante

Dateline NBC

'Dateline NBC,' the signature broadcast for NBC News in primetime, premiered in 1992. Since then, it has been pioneering a new approach to primetime news programming. The multi-night franchise, supplemented by frequent specials, allows NBC to consistently and comprehensively present the highest-quality reporting, investigative features, breaking news coverage and newsmaker profiles.

Source: http://www.nbcnews.com/id/3032600/vp/50746760#50746760

shabazz muhammad angela corey zimmerman charged bonobos charles manson al sharpton actuary

Video: Sen. Paul: Sequester Barely Cuts Any Icing From Cake

Sorry, Readability was unable to parse this page for content.

Source: http://video.msnbc.msn.com/cnbc/50735654/

hoodie hoosiers temperance world bank kim kardashian flour bomb hunger games box office xavier